Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Juiwanna Kushner"'
Autor:
Xinan Qiao, Jun Ma, Tristan Knight, Yongwei Su, Holly Edwards, Lisa Polin, Jing Li, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Jian Wang, Hai Lin, Yue Wang, Liping Wang, Guan Wang, Jeffrey W. Taub, Yubin Ge
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 6, Pp 1-17 (2021)
Abstract About 25% of patients with acute myeloid leukemia (AML) harbor FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations and their prognosis remains poor. Gilteritinib is a FLT3 inhibitor approved by the US FDA for use in
Externí odkaz:
https://doaj.org/article/70d217bd11434be4bbb6948db97bb9fd
Autor:
Xinyu Li, Yongwei Su, Katie Hege, Gerard Madlambayan, Holly Edwards, Tristan Knight, Lisa Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Jay Yang, Regan Miller, Guan Wang, Lijing Zhao, Yue Wang, Hai Lin, Jeffrey W. Taub, Yubin Ge
Publikováno v:
Haematologica, Vol 106, Iss 5 (2020)
Venetoclax is a promising agent in the treatment of acute myeloid leukemia, though its antileukemic activity is limited to combination therapies. Mcl-1 downregulation, Bim upregulation, and DNA damage have been identified as potential ways to enhance
Externí odkaz:
https://doaj.org/article/3e3e34e78f4b4b259f1f44a78a6c22ea
Autor:
Xinyu Li, Yongwei Su, Gerard Madlambayan, Holly Edwards, Lisa Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Jun Ma, Tristan Knight, Guan Wang, Yue Wang, Jay Yang, Jeffrey W. Taub, Hai Lin, Yubin Ge
Publikováno v:
Haematologica, Vol 104, Iss 11 (2019)
Induction therapy for patients with acute myeloid leukemia (AML) has remained largely unchanged for over 40 years, while overall survival rates remain unacceptably low, highlighting the need for new therapies. The PI3K/Akt pathway is constitutively a
Externí odkaz:
https://doaj.org/article/f997a12ee3164750a553d1a5d8fd8e8e
Autor:
Natalia Baran, Katie Hurrish, Yongwei Su, Shraddha Patel, Cassandra Ramage, Jenna Carter, Holly Edwards, Steven Buck, Sandra Wiley, Maik Hüttemann, Lisa Polin, Juiwanna Kushner, Sijana Dzinic, Kathryn White, Xun Bao, Jing Li, Jay Yang, Julie Boerner, Zhanjun Hou, Gheath Al-Atrash, Sergej Konoplev, Jonathan Busquets, Stefano Tiziani, Larry Matherly, Jeffrey Taub, Marina Konopleva, Yubin Ge
Venetoclax (VEN), in combination with low dose cytarabine (AraC) or a hypomethylating agent, is FDA approved to treat acute myeloid leukemia (AML) in patients who are over the age of 75 or cannot tolerate standard chemotherapy. Despite high response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a03d99a8c2a425123fb511654ec9d36e
https://doi.org/10.21203/rs.3.rs-2843025/v1
https://doi.org/10.21203/rs.3.rs-2843025/v1
Autor:
Larry H. Matherly, Aleem Gangjee, Robert T. Morris, Juiwanna Kushner, Kathryn White, Lisa Polin, Steve Orr, Christina George, Adrianne Wallace-Povirk, Si Yang, Carrie O'Connor, Leda Gattoc, Zhanjun Hou
Table S1: Epithelial ovarian cancer (EOC) tissue cDNA array for real-time RT-PCR (Figures 2A and 2B). Table S2. Epithelial ovarian cancer (EOC) tissue microarray (TMA) for immunohistochemistry (IHC; Figures 2C and 2D).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17f1ed0a289afe9ae49b45238fff404d
https://doi.org/10.1158/1535-7163.22504539.v1
https://doi.org/10.1158/1535-7163.22504539.v1
Autor:
Larry H. Matherly, Aleem Gangjee, Charles E. Dann, Zhanjun Hou, Jing Li, Joshua D. Rabinowitz, Lisa Polin, Maik Hüttemann, Seongho Kim, Juiwanna Kushner, Kathryn White, Sijana H. Dzinic, Carrie O'Connor, Adrianne Wallace-Povirk, Jenney Liu, Josephine Frühauf, Xun Bao, Changwen Ning, Arpit Doshi, Md. Junayed Nayeen, Jennifer Wong-Roushar, Jade M. Katinas, Gregory S. Ducker, Khushbu Shah, Aamod S. Dekhne
Supplementary Figure S1 shows in vitro antiproliferative activity and targeted pathways of previously reported AICARFTase and GARFTase inhibitors. Supplementary Figure S2 shows docking of AGF291, AGF320, and AGF347 (along with 5-formyl-THF) in human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f58160726ffe67fe411c78ec2698b22
https://doi.org/10.1158/1535-7163.22505523.v1
https://doi.org/10.1158/1535-7163.22505523.v1
Autor:
Yubin Ge, Jeffrey W. Taub, Yue Wang, Hai Lin, Lijing Zhao, Guan Wang, Kathryn White, Sijana H. Dzinic, Juiwanna Kushner, Lisa Polin, Holly Edwards, Tristan Knight, Xinan Qiao, Shoujing Zhao, Jun Ma
Purpose:To investigate the efficacy of the combination of the FLT3 inhibitors midostaurin or gilteritinib with the Bcl-2 inhibitor venetoclax in FLT3-internal tandem duplication (ITD) acute myeloid leukemia (AML) and the underlying molecular mechanis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d1c4c63610979404875496c09ea9a4d
https://doi.org/10.1158/1078-0432.c.6528239
https://doi.org/10.1158/1078-0432.c.6528239
Autor:
Yubin Ge, Jeffrey W. Taub, Yue Wang, Hai Lin, Lijing Zhao, Guan Wang, Kathryn White, Sijana H. Dzinic, Juiwanna Kushner, Lisa Polin, Holly Edwards, Tristan Knight, Xinan Qiao, Shoujing Zhao, Jun Ma
Table S1 shows patient characteristics and Figure S1 shows preliminary efficacy results
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c60b6f4b01f7ab92fc0da848f42d7f76
https://doi.org/10.1158/1078-0432.22472489.v1
https://doi.org/10.1158/1078-0432.22472489.v1
Autor:
Aamod S. Dekhne, Khushbu Shah, Gregory S. Ducker, Jade M. Katinas, Jennifer Wong-Roushar, Md. Junayed Nayeen, Arpit Doshi, Changwen Ning, Xun Bao, Josephine Frühauf, Jenney Liu, Adrianne Wallace-Povirk, Carrie O'Connor, Sijana H. Dzinic, Kathryn White, Juiwanna Kushner, Seongho Kim, Maik Hüttemann, Lisa Polin, Joshua D. Rabinowitz, Jing Li, Zhanjun Hou, Charles E. Dann, Aleem Gangjee, Larry H. Matherly
Publikováno v:
Molecular Cancer Therapeutics. 22:287-287
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77add014c1f088eaf12406ee9ad8e4d9
https://doi.org/10.1158/1535-7163.mct-22-0766
https://doi.org/10.1158/1535-7163.mct-22-0766
Autor:
Jun Ma, Yubin Ge, Tristan Knight, Guan Wang, Juiwanna Kushner, Yue Wang, Hai Lin, Liping Wang, Xinan Qiao, Kathryn White, Lisa Polin, Holly Edwards, Sijana H. Dzinic, Yongwei Su, Jeffrey W. Taub, Jing Li, Jian Wang
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 6, Pp 1-17 (2021)
Blood Cancer Journal
Blood Cancer Journal
About 25% of patients with acute myeloid leukemia (AML) harbor FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations and their prognosis remains poor. Gilteritinib is a FLT3 inhibitor approved by the US FDA for use in adult FL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03e84c3b82afe1dca09afa44dd2cf874
https://doi.org/10.1038/s41408-021-00502-7
https://doi.org/10.1038/s41408-021-00502-7